NCT06805617 - A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Salivary Gland CancerAdvanced Salivary Gland CarcinomaMetastatic Salivary Gland CancerAdenoid Cystic Carcinoma

Interventions

DRUG

Ivonescimab

An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial, via intravenous (into the vein) infusion per protocol.

Trial Locations (2)

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston